National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

vandetanib
An orally bioavailable 4-anilinoquinazoline. Vandetanib selectively inhibits the tyrosine kinase activity of vascular endothelial growth factor receptor 2 (VEGF2), thereby blocking VEGF-stimulated endothelial cell proliferation and migration and reducing tumor vessel permeability. This agent also blocks the tyrosine kinase activity of epidermal growth factor receptor (EGFR), a receptor tyrosine kinase that mediates tumor cell proliferation and migration and angiogenesis. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

US brand name:Zactima
Code names:AZD6474
ZD6474



Previous:valspodar, Valstar, Valtrex, Vancenase, Vanceril
Next:Vantin, Vaqta, varenicline, vascular disrupting agent CYT997, Vasomax

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov